Clinical Outcomes in Patients with Multi-Hit <i>TP53</i> Chronic Lymphocytic Leukemia Treated with Ibrutinib

Abstract

In this study, single-hit <i>TP53</i> defines a distinct subgroup of patients with an excellent long-term response to single-agent ibrutinib, whereas multi-hit <i>TP5</i>3 is independently associated with shorter PFS. These results warrant further investigations on prognostication and management of multi-hit <i>TP53</i> CLL.<i>See related commentary by Bomben et al., p. 4462</i>.